<DOC>
	<DOCNO>NCT00654550</DOCNO>
	<brief_summary>Phase 1 randomize , prospective , double-masked , vehicle-controlled , dose-escalation study evaluate safety , tolerability clinical effect Nexagon™ subject follow bilateral PRK correction mild moderate myopia .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Effect Nexagon™ Applied Eye After PRK Laser Eye Surgery Nearsightedness</brief_title>
	<detailed_description />
	<criteria>Male female prepresbyopic myope . Aged 20 50 year inclusive . Females eligible participate currently nonpregnant nonlactating . Females childbearing potential must commit consistent correct use acceptable method birth control . Subjects willing able undergo bilateral PRK correction myopia . Subjects MRSE &lt; 6.0 D , less 2.0 D astigmatism . No 1.0 D refractive difference eye . Stable prescription eye define &lt; 0.25 D change precede 2 year . Subjects able comply study procedure , include wear soft bandage contact lens immediate postoperative period . Subjects willing able give write informed consent take part study . Subjects past present disease , judge investigator may affect safety subject outcome study . Subjects previously corneal surgery . Subjects require Mitomycin C follow PRK . Subjects ocular disease corneal abnormality , include limited : Decreased corneal sensation / neurotrophic cornea ; Corneal vascularization ; Keratoconus ; Keratoconjunctivitis sicca require chronic treatment ; Lagophthalmos ; Blepharitis ; History infectious keratitis ; History glaucoma intraocular pressure &gt; 21 mmHg use glaucoma medication ; Significant dry eye disease require regular topical treatment ; Corneal thickness &lt; 480 µm thinnest point , Posterior elevation &gt; 40 mmHg . Subjects corneal haze &gt; +1 assess use grade scale protocol . Subjects require topical ophthalmic medication pre postoperative regimen define study protocol . Subjects : Diabetes ; Collagen disorder associate autoimmune disease , e.g. , lupus , rheumatoid arthritis ; Severe atopic disease ; Any systemic disease condition subject immunocompromized . Subjects require systemic medication affect heal , e.g. , steroid , hormone replacement therapy . Subjects take amiodarone , long act anticholinergic , e.g. , atropine , scopolamine , medication agent cause dry eye . Subjects participate clinical trial within 30 day prior date PRK schedule .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Photorefractive keratectomy</keyword>
	<keyword>Re-epithelialization</keyword>
	<keyword>Nexagon</keyword>
	<keyword>PRK</keyword>
	<keyword>Coda</keyword>
</DOC>